


In Silico Prediction Of Genotoxicity: Current Applications And Future Perspectives

Alex Cayley

Senior Scientist

alex.cayley@lhasalimited.org



Overview

- Who Lhasa are and what we do
- General approaches to *in silico* genotoxicity prediction
- How *in silico* predictions can be used in the pharmaceutical development process
- How *in silico* predictions for toxicity (in Derek Nexus) currently account for metabolism
- How *in silico* predictions might develop and be used in the future

Introduction to Lhasa Limited

- Established in 1983
- HQ located in Leeds, United Kingdom
- Not-for-profit & Educational Charity
- Facilitate collaborative data sharing projects in the chemistry-related industries
- Controlled by our members
- Creators of knowledge base, statistical and database systems




Origins of *in silico* genotoxicity prediction

Mutat Res. 1988 Jan;204(1):17-115.

Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP.

Ashby J¹, Tennant RW.



DEREK
Oncologic
Toxtree (Benigni-Bossa rulebase)

$C(X)_4$ **t**
X= H, F, Cl, Br, I (in any combination)

Development of *in silico* genotoxicity prediction



Alert - Found: 1 records

Alert ID: 262

352: Aromatic amine or amide

Alert Matches

KB: DKE2 AC1_2018.1 ID: 10978 Links (57) State: Enabled

Identifiers:

Identifier: 746

Name: Arylboronic acid or derivative


Description Image:

Description


Mutagenicity: Ames test

This alert describes the activity of arylboronic acids and their esters (I), arylboroxines (II) and aryltrihalo-borate salts (III) in the Ames test. Activity in this assay has been observed for 85 compounds from a data set which contains 96 proprietary compounds donated by Lhasa Limited members and 53 published compounds [O'Donovan et al, Hansen et al]. Examples include 2,4,6-tris(3,5-difluorophenyl)boroxine, 2-fluoro-6-methoxyphenylboronic acid, 4-cyanophenylboronic acid [O'Donovan et al], pyrimidine-5-boronic acid and benzo[b]thiophene-2-boronic acid [Hansen et al]. Many of the compounds in this class only produce weak positive results in the Ames test. In some cases a doubling in revertant count is not achieved, however a dose

2. Ortho disubstitution of the amine or amide group by substituents other than fluorine or NH₂ or NH₃⁺ is not permitted except in biphenyl-type structures where an aromatic substituent is additionally present in the para position.




2004	2005	2018
4	7	8



132 alerts for Mutagenicity in Derek Nexus 2018.1



Origins of *in silico* genotoxicity prediction



Development of *in silico* genotoxicity prediction

Sarah Predict... Sarah Predict... Results Additional Information (14)

For the 'Mutagenicity in vitro' endpoint the prediction is:

POSITIVE

with **59%** confidence

Click above to view the original structure

Prediction Constraints

Model: Sarah Model - 2.0
Endpoint: Mutagenicity in vitro
Reasoning type: Weighted
Equivocal: 8%
Sensitivity: 8%
Certified model: Yes
Prediction date: 22 September 2018 21:19

Highlight Hypotheses and Features: ☒ ☐ + - Strain

The compound is predicted to be positive with 59% confidence for the 'Mutagenicity in vitro' endpoint in the model: 'Sarah Model - 2.0'. Supporting hypotheses containing similar examples from the training set have been found.

Hypothesis

AROM

Positive 69%

Hypothesis

Positive 44%

Training set examples Showing 50 examples (50/974)

1 of 50 - 55% (+Ve)	2 of 50 - 55% (+Ve)	3 of 50 - 48% (+Ve)
4 of 50 - 48% (+Ve)	5 of 50 - 48% (+Ve)	6 of 50 - 48% (+Ve)
7 of 50 - 44% (+Ve)	8 of 50 - 42% (+Ve)	9 of 50 - 42% (+Ve)
10 of 50 - 42% (+Ve)	11 of 50 - 40% (+Ve)	12 of 50 - 37% (-Ve)
13 of 50 - 36% (+Ve)	14 of 50 - 36% (+Ve)	15 of 50 - 35% (-Ve)

Example compound

Overall Call: Positive
Similarity: 42%

Click on a contribution below to view the original structure

Source: Vitic Nexus Summary Call Table
Dataset Call: Positive
Source Activity Call: Positive
Structure ID: 95-78-3

Reference(s)

Source: ISSSTY Mutagenicity Dataset
Dataset Call: Positive
Source Activity Call: Positive
Structure ID: 95-78-3

Features Of Different Approaches

- Physicochemical properties can also be used as descriptors by both types of model (CLogP, HOMO, LUMO)

Expert Rule	Statistical Approach
Correlation usually causative	Correlation may not be causative
Slower To Implement	Quick To implement
Rules can be based on theory alone	Large data set required
Highly interpretable	May not be as interpretable
Able to deal with 'noise' in the data	More prone to errors in data
Risk of overfitting	Risk of overfitting

How Well Do They Perform?

- Against Ames mutagenicity data sets, pretty well but will depend on chemical space (better against published data than private)
- Expert review improves results
- For other genotoxicity endpoints more work is required

Performance Metric	Average Performance (Public)	Average Performance (Proprietary)
Balanced Accuracy	77%	66%
Sensitivity	74%	58%
Specificity	81%	73%
Coverage	95%	92%




Fig. 1. A box and whisker plot comparing the balanced accuracy (sensitivity + specificity/2) of Ames mutagenicity predictions for publicly available versus proprietary data. The top and bottom edges of each box represent the third and first quartile balanced accuracy values for each set and the line in the middle of the box represents the median value. The whiskers illustrate the maximum and minimum values for each set.

Barber *et al.*; Reg. Tox. Pharm.; 2016; 76; 7-20
<https://www.ncbi.nlm.nih.gov/pubmed/26708083>

Dobo *et al.*; Reg. Tox. Pharm.; 2012; 62; 449-455
<https://www.ncbi.nlm.nih.gov/pubmed/22321701>



Considerations Of Metabolism

Why is metabolism important?

- Non-genotoxic species may have genotoxic metabolites
- Potentially genotoxic species may be deactivated by metabolism

How Do We deal With Metabolism Currently?


- Let the assay take care of it and model the assay results
- Encode the metabolism in the model
- Predict metabolism and then predict toxicity



R1, R2 = H, C (not multiply bound or attached to any heteroatoms)
R3, R4 = H, C


Considerations Of Metabolism

Type Of Alert	Number Of Alerts
All mutagenicity endpoint	132
Mutagenicity requiring metabolism	46
Direct mutagenicity	58
Mixed requirement	20
Unknown	8



When Are *In Silico* Predictions Used?

- Where a chemical is not available for testing
- Where testing would be prohibitively expensive (large number of chemicals)
- Where time is of the essence (large number of chemicals)
- To prioritise future work
- Where guidelines indicate that *in silico* predictions can be used in place of other tests



What Could Be Improved?


- Better coverage of mechanisms/endpoints leading to genotoxicity not covered by Ames test (mainly electrophilic reactivity)
- Better advice about what to do next following a prediction
- Better integration with other available evidence (*in vitro*, *in vivo* genotoxicity assays and bioassays)
- More transparent information about mechanism causing toxicity, leading to better models
- More information about metabolism activating or deactivating compound
- Relevance beyond the species/test being modelled
- Moving from hazard to risk prediction (less binary, more quantitative predictions)

The Adverse Outcome Pathway Framework

What is an Adverse Outcome Pathway?

The OECD launched a new programme on the development of **Adverse Outcome Pathways (AOP)** in 2012. An AOP is an analytical construct that describes a sequential chain of causally linked events at different levels of biological organisation that lead to an adverse health or ecotoxicological effect (see figure below). AOPs are the central element of a toxicological knowledge framework being built to support chemical risk assessment based on mechanistic reasoning.

Schematic representation of the AOP illustrated with reference to a number of pathways:




What Could Be Improved?


- Better coverage of mechanisms/endpoints leading to genotoxicity not covered by Ames test (mainly electrophilic reactivity) **Easier To Identify Holes And Use More Data To fill Them**
- Better advice about what to do next following a prediction ✓
- Better integration with other available evidence (*in vitro*, *in vivo* genotoxicity assays and bioassays) ✓
- More transparent information about mechanism causing toxicity, leading to better models ✓
- More information about metabolism activating or deactivating compound **Easier To Predict Metabolism In Correct Context**
- Relevance beyond the species/test being modelled ✓
- Moving from hazard to risk prediction (less binary, more quantitative predictions) ✓

The Future - AOPs

707: Diaryl ketone



R1 = C (aromatic)
C# cannot be part of a ring fusion
N atoms bonded to an aromatic carbon are not allowed anywhere



- ▲ Derek KB 2018 1.1 [Certified by: Lhasa Limited, Leeds, Yorkshire, UK]
- ▲ Carcinogenicity
 - ▲ mammal - PROBABLE
 - Alert - 707: Diaryl ketone
 - Example - benzophenone

▼ Comments

Diaryl ketones have been shown to display carcinogenic activity in rats and mice. Examples include isoxaflutole [US EPA 2009], topramezone [US EPA 2009] and benzophenone [NTP 2006]. Isoxaflutole has been classified as a group B2 carcinogen (probable human carcinogen with little or no human data) by the United States Environmental Protection Agency [US EPA 1998]. It induced adenomas and carcinomas in the rat liver and thyroid glands whereas in the mice it only induced hepatocellular adenomas and carcinomas [US EPA 1998]. In a 2 year feeding study in rats, benzophenone induced renal tubule adenomas (in males only) and mononuclear cell leukaemia. In mice, benzophenone increased the incidence of hepatocellular adenomas and histiocytic sarcoma (in females only) [NTP 2006].

The carcinogenicity of diaryl ketones occurs through a non-genotoxic mechanism. Benzophenone has been shown to bind to the pregnane X receptor (PXR) in vitro which is a specific inducer of CYP3A, CYP2B and CYP2C enzymes [Mikamo et al]. In a short-term study, exposure to benzophenone was associated with hepatocellular hypertrophy and cell proliferation and was accompanied by an induction of CYP2B [NTP 2000]. These effects are similar to those seen with barbituric acids such as phenobarbital, which are non-genotoxic carcinogens (their activity is described elsewhere in the knowledge base). It is deemed unlikely that the carcinogenic activity of compounds acting through a phenobarbital-like mechanism can be extrapolated to humans [Holsapple et al], although in this case the link is based on limited data and should not be considered as conclusive.



Query Compound

Adverse outcome

Molecular initiating event


Key event

The Future - AOPs




The Future - AOPs

I am only interested in pathways leading to direct damage to DNA




The Future - AOPs

I am only interested in pathways leading to direct damage to DNA



The Future - AOPs


I am only interested in pathways leading to direct damage to DNA



Integrate other information with network

The Future - AOPs

I am only interested in pathways leading to direct damage to DNA



Integrate other information with network


In Vitro Assays

In Vivo Assays

Gene/Protein expression

The Future - AOPs

I am only interested in pathways leading to direct damage to DNA




Integrate appropriate models with the network

Better selection of descriptors/
modelling techniques
More data available

Integrate other information with network

In Vitro Assays
In Vivo Assays
Gene/Protein expression

Integrating Pathways With Assay Data



Integrating Pathways With Assay Data

Environ Mol Mutagen. 2016 Apr;57(3):171-89. doi: 10.1002/em.21996. Epub 2016 Jan 13.


Genotoxic mode of action predictions from a multiplexed flow cytometric assay and a machine learning approach.

Bryce SM¹, Bernacki DT¹, Bemis JC¹, Dertinger SD¹.

[Author information](#)

Abstract

Several endpoints associated with cellular responses to DNA damage as well as overt cytotoxicity were multiplexed into a miniaturized, "add and read" type flow cytometric assay. Reagents included a detergent to liberate nuclei, RNase and propidium iodide to serve as a pan-DNA dye, fluorescent antibodies against γ H2AX, phospho-histone H3, and p53, and fluorescent microspheres for absolute nuclei counts. The assay was applied to TK6 cells and 67 diverse reference chemicals that served as a training set. Exposure was for 24 hrs in 96-well plates, and unless precipitation or foreknowledge about cytotoxicity suggested otherwise, the highest concentration was 1 mM. At 4- and 24-hrs aliquots were removed and added to microtiter plates containing the reagent mix. Following a brief incubation period robotic sampling




The Benefits

- 1) Allows for cutting of the knowledge in different ways depending on use case
- 2) Allows for custom model building using descriptors appropriate to that MIE/KE
- 3) Allows for more precise hypothesis testing following a prediction
- 4) Allows for closer integration with emerging *in vitro* and *in vivo* assays
- 5) Allows for integration with other toxicity endpoints
- 6) Many more...

Additional Considerations

- 1) Assess exposure qualitatively and quantitatively (ADME)
- 2) Make predictions quantitative
- 3) Make *in vitro* to *in vivo* extrapolations (IVIVE)
- 4) Make risk assessments
- 5) Make an assessment of human relevance

The Future



Conclusions

- *In silico* prediction of genotoxicity has come a long way since its inception
- The predictions for these endpoints are embedded in the development process in a number of different places and are already proving their worth
- There is still room for improvement, particularly for predictions which do not relate to direct reaction with DNA
- These predictions may be improved by,
 - More work
 - Better models utilising all data available
 - Better integration of all available evidence
- AOPs are a promising way of achieving these things as well as providing scope for extending beyond hazard prediction to prediction of human risk

Questions?



Work in progress disclaimer

This document is intended to outline our general product direction and is for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon. The development, release, and timing of any features or functionality described for Lhasa Limited's products remains at the sole discretion of Lhasa Limited.

